Is Bolt Biotherapeutics, Inc. (BOLT) a Buy, Sell, or Hold?
NASDAQ : BOLT
Bolt Biotherapeutics, Inc.
$4.035 USD
-$0.01 (-0.37%)
- Volume
- 7.58K
- Average Volume
- 25.24K
- Market Capitalization
- $7.75M
- P/E Ratio
- -0.25
- Dividend Yield
- 0.00%
- Price Target
- $4.00
- Year High
- $7.20
- Year Low
- $3.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.51
Company Overview
NASDAQ
William Quinn
Biotechnology
Healthcare
BOLT
23
US
USD
Liquidity Metrics
1.13
3.51
3.51
1.58
0.00
Sales & Valuation
$7.7M
1.19
0.38
-0.22
-18.49
Profitability
-$17.85
-$33.38M
-455.15%
-455.15%
-100.90%
-61.59%
P/E Metrics
-0.25
0.00
0.00
Analyst Price Target & Rating
$4.00
$7.00
$1.00
2/5
8 Analysts
0.88%
Financial Health Scores
-14.91
3/9
$18.41M
$48.03M
$28.2M
-$29.58M
Key Metrics (TTM)
$18.48M
2.84
-0.65
3.51
-100.90%
-69.02%
-390.59%
-444.34%
-3121 days
Company Executives
| Name | Title |
|---|---|
| Michael N. Alonso | Senior Vice President of Research |
| Grant Yonehiro | Chief Operating Officer & Chief Business Officer |
| Justin Kenkel | Senior Principal Scientist |
| William Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director |
| Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer |
Poll Results
No votes yet today — be the first to share your view!
About Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Stock
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin- ... 2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project
2026-06-12 07:00:00
VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity controlled by Max Resource Corp. ("Max"), pursuant to which Bolt has the right to acquire 100% of the Florália High Purity Iron Property (title no.
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-12 18:40:22
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-12 16:05:00
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
Frequently Asked Questions
-
What is the current Bolt Biotherapeutics, Inc. (BOLT) stock price?
-
Bolt Biotherapeutics, Inc.(NASDAQ:BOLT) stock price is $4.035 in the last trading session. During the trading session, BOLT stock reached the peak price of $7.2 while $3.75 was the lowest point it dropped to. The percentage change in BOLT stock occurred in the recent session was --0.37% while the dollar amount for the price change in BOLT stock was -$0.01.
-
BOLT's industry and sector of operation?
-
The NASDAQ listed BOLT is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BOLT?
-
Michael N. Alonso | Senior Vice President of Research
Grant Yonehiro | Chief Operating Officer & Chief Business Officer
Justin Kenkel | Senior Principal Scientist
William Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary & Director
Sarah Nemec | Senior Vice President of Finance & Principal Accounting Officer -
How many employees does BOLT have?
-
Number of BOLT employees currently stands at 23. BOLT operates from 900 Chesapeake Drive, Redwood City, CA 94063, US.
-
Link for BOLT official website?
-
Official Website of BOLT is: https://www.boltbio.com
-
How do I contact BOLT?
-
BOLT could be contacted at phone #650 665 9295 and can also be accessed through its website. BOLT operates from 900 Chesapeake Drive, Redwood City, CA 94063, US.
-
How many shares of BOLT are traded daily?
-
The average number of BOLT shares traded daily for last 3 months was 25.24K.
-
What is the market cap of BOLT currently?
-
The market value of BOLT currently stands at $7.75M with its latest stock price at $4.035